Issue Contents
|
|
Marketing Authorisations
|
|
|
|
|
Only 8 weeks of treatment for many patients
|
|
|
|
|
|
|
|
|
|
Additional data show no excess cardiovascular risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Very little advantage from adding clopidogrel to aspirin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The complete contents of
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated.
